U.S. Markets open in 2 hrs 32 mins

Clovis Oncology, Inc. (CLVS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
54.44+2.20 (+4.21%)
At close: 4:00PM EDT
People also watch
  • Another good news that Rubraca is also a miracle drug to treat autoimmune diseases such as rheumatoid arthritis perhaps for its inducing expression of pd1 and ctla4. It will be a huge breakthrough. Notably, the induced pd1/ clta4 by Rubraca enhance the efficiency of anti pd1 & clta4 drug against cancer.
  • All 8 advanced ovarian cancer, very sick patients were treated with Rubraca in one clinic and are now cancer free though maintaining with Rubraca at 200mg dose. It is a miracle.
  • market up....wtfigo? 8% ystrdy and people take profit? r u nuts?
  • The chart looks very good. MACD and SMA50 divergence pointing to a breakout
  • Harry Boxer has posted his Charts of the Day video on CLVS at TheTechTrader site noting: Clovis Oncology Inc (CLVS) jumped 4.13, or 8%, to 54.63, on 2.2 million shares traded on Thursday. It has been up five days in a row, and had an exceptional rally back. It had a 3-wave corrective move in a larger rising channel. If that’s the case, especially if it gets up to the 58-60 range, not only does it take out lateral resistance, but it will complete taking out the declining topsline and 50-day moving average. It could take another run into the mid 60’s, and then the mid 70’s. Eventually, it will get much higher than that. Even a rally mid-range would get it to 65.
  • looks great is Gilead making The Move
  • Clovis, Tesaro, AstraZeneca rating change at JPMorgan Clovis upgraded to Overweight from Neutral at JPMorgan. JPMorgan analyst Cory Kasimov upgraded Clovis Oncology (CLVS) to Overweight and raised his price target for the shares to $72 from $58. The stock closed yesterday up 2%, or $1.05, to $49.56. The shares are down 35% over the last two months for "no clear fundamental reason," Kasimov tells investors in a research note. The analyst is "increasingly comfortable" recommending Clovis ahead of its Phase 3 study evaluating Rubraca in maintenance ovarian cancer now that more PARP class data has emerged. He has not seen "convincing evidence" that there is a clear efficacy difference between Clovis' rucaparib, Tesaro's (TSRO) niraparib and AstraZeneca's (AZN) olaparib. Read more at: http://thefly.com/landingPageNews.php?id=2553683

    Read more at:

    Clovis upgraded to Overweight from Neutral at JPMorgan CLVS;TSRO;AZN - The Fly
    Designed by market professionals, thefly.com has been reporting unbiased market intelligence to both professional and individual investors for more than 12 years. With information directly sourced from Wall Street traders, brokers, and institutional
  • Clinicians & patients all talk good of Rubraca, a very good sign.
  • Studies seem to indicate that Tesaro's recently approved niraparib is more effective and has wider use than Clovis' rupacarib. You would think doctors will choose AZN's Lynparza or niraparib first.
  • Also Check out INCY report, their results are not so impressive, across board is 30% RR. Clearly PARP inhibitors are much more promising. Cheer up.
  • Rubraca is the most potent of PARP1 inhibitors as tested in cell free conditions by multiple lab. You can check it out online.
  • it will run as soon as the market calm down a bit. indeed we caught a" bad day " for SUCH GREAT NEWS!
  • "The analyst believes the BRCA population is likely to be on par with other PARP inhibitors (within 3mo PFS benefit based on his doctor checks), but the all-comer result is the most meaningful for Rubraca because a broad label could more than double the addressable population."
    This is a very critical piece of information. The doctor checks means the information is very real-time and yes there could still be surprises, but the comfort level of the CEO and analyst, history of other such trials, and earlier results from Clovis, make me believe that Trial results are Great. CEO also talked about evidence they have (not from trial - but from doctors) about how great it was for other cancers. Overall very positive cycle.....Could propel this higher than 52 week high......
  • CLVS double bottom achieved last week at $45.50.
    The stock is up $4 from that point
    It moves fast so don't be late...
  • Good news is that Rubraca can dramatically sensitize External beam radiation therapy (EBRT) on a pancreatic cancer without Brca1/2 mutation as a clinician observed, proving a long time presumption based upon preclinical and cell culture tests. This is a huge story in oncology field.
  • Here are 10 statistics about the cost of cancer treatment in America as researched by several health and cancer-related organizations:
    67% of the total costs of cancer treatment are non-medical. (American Cancer Society)
    Total annual cost of cancer care in the U.S. is projected to reach $175 billion by 2020, an increase of 40% from 2010. (American Society of Clinical Oncology)

    In another word, if cancer becomes a managable chronic disease as RAs are, and as clinicians recently witness for Rubraca for OC and PC, the whole medical cost structure would improve by 50-60%.


    10 Statistics On The Cost of Cancer Treatment in America
    Here are 10 statistics about the cost of cancer treatment in America through research conducted by several healthcare organizations.
  • we might see 55+ today...and in couple of weeks back to the 70s level. . momentum is in place.
  • I think Lillie is buying. Blue Horse Shoe is back!
  • Revenues to triple in '18 vs '17. Don't see that very often!